Tortugas Neuroscience Launches with $106 Million to Advance Clinical Stage Pipeline Targeting New and Major Neurology and Neuropsychiatric Disorders

海龟神经科学公司启动，获1.06亿美元资金，用于推进针对新型及主要神经和神经精神疾病的临床阶段管线。

Biotech Veterans Jeff Jonas and Al Robichaud to Lead Company with Investment from Cure Ventures, The Column Group, and AN Ventures

生物技术资深人士杰夫·乔纳斯和阿尔·罗比肖将领导公司，Cure Ventures、The Column Group 和 AN Ventures 投资。

FRAMINGHAM, Mass., April 21, 2026-- Tortugas Neuroscience (“Tortugas”), a neurology-focused biotech company developing novel medicines with derisked mechanisms of actions, for large and well-defined indications, today announces $106 million in Seed and Series A financings. The funding will support ongoing research and development initiatives, including the completion of Phase 2 clinical trials for its two lead candidates..

马萨诸塞州弗雷明汉，2026年4月21日——专注于神经病学的生物技术公司Tortugas Neuroscience（“Tortugas”）致力于开发针对明确适应症的具有降低风险作用机制的新型药物，今天宣布完成了1.06亿美元的种子轮和A轮融资。这笔资金将用于支持正在进行的研发计划，包括完成其两个主要候选药物的二期临床试验。

Founding investor Cure Ventures, a life sciences venture capital firm focusing on de novo company formation around groundbreaking technologies, led the Seed round, and will co-lead the Series A round along with The Column Group and AN Venture Partners.

创始投资者Cure Ventures是一家专注于围绕突破性技术进行全新公司组建的生命科学风险投资公司，领投了种子轮融资，并将与The Column Group和AN Venture Partners共同领投A轮融资。

In-licensed from Eisai Co., Ltd. (Tokyo, Japan) and Jiangsu Hansoh Pharmaceutical Group Ltd. (Greater China), the clinical stage pipeline includes potential treatments for schizophrenia, tinnitus, focal epilepsy, reversible encephalopathies, and other high, unmet need central nervous system (CNS) indications.

从日本东京的卫材株式会社和江苏恒瑞医药集团（大中华区）获得许可的临床阶段管线包括治疗精神分裂症、耳鸣、局灶性癫痫、可逆性脑病及其他高度未满足需求的中枢神经系统（CNS）适应症的潜在疗法。

The programs feature small molecule new chemical entities (NCE’s) with derisked mechanisms of action. Tortugas intends for these molecules to be once-daily, oral formulations with differentiated pharmacological profiles, that also afford indication expansion possibilities..

这些项目的特点是小分子新化学实体（NCE），其作用机制已经过风险降低。Tortugas 打算使这些分子成为每日一次的口服制剂，具有差异化的药理特性，并且还提供了适应症扩展的可能性。

Tortugas is led by accomplished drug developers and biotech company builders CEO, Jeff Jonas, M.D., and President, Head of Research & Development, Al Robichaud, Ph.D., both formerly of Sage Therapeutics. The Company’s strategy focuses on the development of medicines with clear regulatory paths to approval, and advantages that are expected to have a clinically meaningful positive impact on patients’ lives..

Tortugas 由经验丰富的药物研发专家和生物技术公司建设者领导，首席执行官 Jeff Jonas 医学博士和总裁、研发主管 Al Robichaud 博士（两人均曾就职于 Sage Therapeutics）。公司战略专注于开发具有明确监管审批路径的药物，并具备预计将对患者生活产生临床意义积极影响的优势。

'We believe each of our programs are well-positioned for differentiation in the marketplace,' said Jeff Jonas, M.D., CEO of Tortugas Neuroscience. 'Tortugas curated its pipeline for innovative therapeutics that have high potential for clinical differentiation and of reaching their target patient markets.

“我们相信我们的每个项目都能够在市场中实现差异化，”Tortugas Neuroscience首席执行官Jeff Jonas博士说道。“Tortugas精心挑选了其创新治疗药物的管线，这些药物具有很高的临床差异化潜力，并能够成功进入目标患者市场。”

I am confident that with our team’s demonstrated drug development capabilities, we will deliver on our promise to patients in need.”.

我坚信，凭借我们团队展示出的药物研发能力，我们将兑现对有需要的患者的承诺。

'We are driven to improve treatment options for patients suffering with CNS disorders,' said Al Robichaud, President, Head of Research & Development at Tortugas. 'The unmet patient need is indeed immense and we are deeply appreciative of this financial support to help us achieve our goals.”

“我们致力于改善中枢神经系统疾病患者的治疗选择，”Tortugas公司总裁兼研发主管阿尔·罗比查德表示。“患者未满足的需求确实巨大，我们非常感激这一财务支持，以帮助我们实现目标。”

About Tortugas Neuroscience

关于托尔图加神经科学

Tortugas Neuroscience is a neurology-focused biotech company dedicated to developing effective medicines that address diseases of the brain. With a strategic focus on derisked mechanisms and rapid development pathways, Tortugas Neuroscience is committed to creating therapies with meaningful impact for patients worldwide.

Tortugas Neuroscience是一家专注于神经学的生物技术公司，致力于开发针对脑部疾病的高效药物。通过聚焦于降低风险的机制和快速开发路径，Tortugas Neuroscience致力于为全球患者创造具有重大影响的治疗方案。

For more information, please visit: https://www.tortugasneuro.com/..

有关更多信息，请访问：https://www.tortugasneuro.com/..

About Cure Ventures

关于Cure Ventures

Founded in 2021, Cure Ventures is a life sciences venture capital firm focusing on de novo company formation around groundbreaking curative technologies. Above all else, the Cure team leads with respect for people and for science. Led by highly accomplished industry veterans, Cure’s investment thesis is founded on three tenets: a seed funding model that allows Cure to de-risk the science and set companies up for success; genetic validation that increases the probability of success; and embedded Cure operators to drive the best day-to-day decision making in collaboration with founders.

Cure Ventures 成立于2021年，是一家专注于围绕突破性治愈技术进行初创公司孵化的生命科学风险投资公司。最重要的是，Cure团队以对人和科学的尊重为引领。由经验丰富的行业资深人士领导，Cure的投资理念基于三大支柱：一种允许Cure降低科学风险并为企业成功奠定基础的种子资金模式；提高成功概率的基因验证；以及嵌入式Cure运营人员，与创始人协作推动最佳日常决策。

For more information, please visit: www.curevc.com..

欲了解更多信息，请访问：www.curevc.com。

About The Column Group

关于专栏组

The Column Group (TCG) is a leading life sciences venture capital firm that seeks to partner with exceptional scientific founders, entrepreneurs, and executives with a shared vision for building the next generation of drug discovery and development companies. TCG creates and invests in innovative biopharma companies with the potential to become leaders in their respective fields.

柱状集团（TCG）是一家领先的生命科学风险投资公司，致力于与杰出的科学创始人、企业家和高管合作，共同打造下一代药物发现与开发公司。TCG 创立并投资于创新型生物制药公司，这些公司有潜力成为各自领域的领导者。

These companies are strongly supported by the unique and complementary skill sets of TCG’s team, which includes world-renowned scientists, experienced drug developers and company builders. For more information, please visit www.thecolumngroup.com..

这些公司得到了TCG团队独特且互补的技能集的大力支持，团队成员包括世界知名的科学家、经验丰富的药物研发人员和公司建设者。欲了解更多信息，请访问www.thecolumngroup.com。

About AN Venture Partners

关于AN风险投资伙伴

ANV is a Tokyo and San Francisco-based multi-stage, global biotech venture capital firm specializing in bridging innovative science from Japan with the US start-up ecosystem. ANV Fund I is a USD200 million fund that closed in June 2025. The firm was established in 2022 by a group of experienced venture capitalists from Japan and the United States, who have a wealth of experience building start-ups.

ANV是一家总部位于东京和旧金山的多阶段全球生物技术风险投资公司，专注于将日本的创新科学与美国的初创企业生态系统连接起来。ANV基金I是一支于2025年6月完成募集的2亿美元基金。该公司由一群来自日本和美国的经验丰富的风险投资家于2022年创立，他们在创建初创企业方面拥有丰富的经验。

ANV is committed to strengthening Japan’s biotech ecosystem and founded initiatives such as Science2Startup Japan to accelerate ecosystem growth..

ANV致力于加强日本的生物技术生态系统，并发起了诸如Science2Startup Japan等倡议以加速生态系统的成长。

Contact:

联系：

Media Contact:

媒体联系人：

Rachel Ford Hutman

瑞秋·福特·赫特曼

Ford Hutman Media

福特哈特曼媒体

rachel@fordhutmanmedia.com

rachel@fordhutmanmedia.com